U.S. Markets closed

NeuroPace, Inc. (NPCE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
21.68+0.68 (+3.24%)
At close: 4:00PM EDT
21.68 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close21.00
Open21.34
Bid19.00 x 1200
Ask25.00 x 900
Day's Range21.34 - 21.89
52 Week Range18.24 - 27.38
Volume11,328
Avg. Volume130,773
Market Cap526.631M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateJun 03, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • NeuroPace To Report Second Quarter 2021 Financial Results on August 12, 2021
    GlobeNewswire

    NeuroPace To Report Second Quarter 2021 Financial Results on August 12, 2021

    MOUNTAIN VIEW, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the second quarter of 2021 after market close on Thursday, August 12, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time. Investors interested in listening to the

  • Have Insiders Been Buying NeuroPace, Inc. (NASDAQ:NPCE) Shares?
    Simply Wall St.

    Have Insiders Been Buying NeuroPace, Inc. (NASDAQ:NPCE) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • Could This Recently IPOed Medical Device Maker Make You Rich?
    Motley Fool

    Could This Recently IPOed Medical Device Maker Make You Rich?

    NeuroPace (NASDAQ: NPCE), is growing the implantable device market for treating drug-resistant focal epilepsy and setting itself up to dominate it for years to come. With an offering that provides better outcomes than its competition, significant penetration into epilepsy centers across the U.S., and potential label expansions that could just about double its current addressable market, this company could offer significant upside to investors. NeuroPace makes a $50,000 implantable device, the RNS (Responsive Neurostimulation) System, that continuously monitors epilepsy patients' brain activity and responds to patient-specific seizure patterns.